Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.06% | 3.66% | 10.15% | 20.40% | 38.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.06% | 3.66% | 10.15% | 20.40% | 38.43% |
| Cost of Revenue | 19.91% | 17.98% | 22.06% | 26.16% | 28.75% |
| Gross Profit | -6.91% | 0.49% | 7.52% | 19.13% | 40.77% |
| SG&A Expenses | 12.10% | 14.63% | 14.62% | 15.33% | 15.55% |
| Depreciation & Amortization | -48.85% | 32.70% | 85.92% | 85.88% | 89.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.52% | 13.46% | 14.52% | 15.12% | 16.44% |
| Operating Income | -627.31% | -361.94% | -1,329.00% | 81.28% | 115.06% |
| Income Before Tax | -696.03% | -236.87% | -269.82% | -155.09% | 92.77% |
| Income Tax Expenses | -269.20% | -261.37% | -231.92% | 14.92% | 2,059.85% |
| Earnings from Continuing Operations | -153.15% | -232.41% | -301.42% | -205.45% | 83.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.15% | -232.41% | -301.42% | -205.45% | 83.54% |
| EBIT | -627.31% | -361.94% | -1,329.00% | 81.28% | 115.06% |
| EBITDA | -157.76% | -100.91% | -22.32% | 827.70% | 198.24% |
| EPS Basic | -169.24% | -229.22% | -295.43% | -165.63% | 86.20% |
| Normalized Basic EPS | -212.33% | -150.07% | -121.86% | 322.63% | 159.29% |
| EPS Diluted | -118.36% | -239.40% | -326.98% | -161.19% | 82.66% |
| Normalized Diluted EPS | -220.07% | -153.08% | -127.99% | 288.46% | 155.40% |
| Average Basic Shares Outstanding | 4.44% | 4.35% | 4.29% | 4.12% | 3.83% |
| Average Diluted Shares Outstanding | 0.76% | 0.64% | 4.24% | 6.97% | 8.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |